Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Decreases By 46.5%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 401,483 shares, a decrease of 46.5% from the February 12th total of 750,201 shares. Currently, 15.9% of the shares of the stock are sold short. Based on an average daily volume of 158,246 shares, the days-to-cover ratio is currently 2.5 days. Based on an average daily volume of 158,246 shares, the days-to-cover ratio is currently 2.5 days. Currently, 15.9% of the shares of the stock are sold short.

Institutional Trading of Aspire Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of ASBP. Jane Street Group LLC grew its stake in shares of Aspire Biopharma by 2,252.1% in the 4th quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock worth $91,000 after buying an additional 658,886 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Aspire Biopharma by 853.2% in the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after acquiring an additional 237,620 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in Aspire Biopharma in the third quarter worth about $28,000. 19.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ASBP has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Aspire Biopharma currently has a consensus rating of “Sell”.

Aspire Biopharma Stock Performance

Shares of ASBP stock traded down $0.08 during mid-day trading on Friday, hitting $1.05. The company’s stock had a trading volume of 93,797 shares, compared to its average volume of 1,142,502. Aspire Biopharma has a 52-week low of $1.07 and a 52-week high of $35.01. The stock has a market cap of $2.82 million, a price-to-earnings ratio of -0.05 and a beta of 0.88. The business has a 50-day moving average price of $2.01 and a 200 day moving average price of $7.96.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.